X

Drug Profile

Research programme: cancer therapeutics - Paradigm Therapeutics

Alternative Names: AMX 202

Latest Information Update: 12 Feb 2008

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Paradigm Therapeutics
Developer Takeda Cambridge
Class Antineoplastics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cancer

Most Recent Events

27 Apr 2007 No development reported - Preclinical for Cancer in United Kingdom (unspecified route)
10 Jan 2005 Amedis Pharmaceuticals has been acquired and merged into Paradigm Therapeutics
28 Jun 2004 AMX 202 is available for partnering (http://www.amedis-pharma.com)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com